

Medical Human Subjects Research – Some of the Changes To Common Rule; Effective Date 7/19/2018

Category	Changes	Comments
Definitions		
<ul style="list-style-type: none"> Human Subject 	Individual about whom investigator obtains, uses, studies, analyzes, or generates identifiable private data	<ul style="list-style-type: none"> Retains “readily identifiable” standard, NOT HIPAA standard; does NOT include DE-identified data or specimens; “identifiable” to be re-examined every 4 years by Feds
<ul style="list-style-type: none"> Clinical Trial 	Prospective assignment of subjects to evaluate biomedical or behavioral health-related outcomes.	
<ul style="list-style-type: none"> Not Research 	<ol style="list-style-type: none"> Scholarly/Journalistic activities Public Health Surveillance Criminal Justice agency research Intelligence Agency / Homeland Security research 	Confirmation of <u>current practice</u>
<ul style="list-style-type: none"> Limited IRB Review 	Required for some Exemptions. IRB must review: privacy; confidentiality of data; broad consent	More like Expedited review, not Exempt
<ul style="list-style-type: none"> Broad Consent 	12 Elements required: <ul style="list-style-type: none"> Risks Benefits Confidentiality of Data Voluntary Commercial Profit Whole Genome Sequencing Types of Future Research Description of identifiable data/specimens, what identifiers, will sharing occur and with whom 	<ul style="list-style-type: none"> Optional alternative to study-specific consent; for secondary use of identifiable private data and specimens for <u>unspecified</u> future research Elements of Broad Consent may not be waived or altered.

Medical Human Subjects Research – Some of the Changes To Common Rule; Effective Date 7/19/2018

Category	Changes	Comments
	<ul style="list-style-type: none"> • Duration of storage/use (can be indefinite) • Statement that subjects will not be informed of specific future research • Results may not be disclosed • Whom to contact for questions 	
Exempt Research		
<ul style="list-style-type: none"> • Interactions via surveys, interview 	If: 1. not identifiable; 2. no risk; OR 3. identifiable <u>with</u> potential risk <u>and</u> limited IRB review required	<u>Not</u> with children; pregnant women okay; <u>incidental</u> inclusion of prisoners okay.
<ul style="list-style-type: none"> • Benign behavioral interventions: Brief, harmless, painless, not invasive, offensive/embarrassing 	Same as above	With prospective agreement of adult subjects only; No deception unless prospective subject agreement;
<ul style="list-style-type: none"> • Secondary research with identifiable data for which no consent required if: 	<ol style="list-style-type: none"> 1. publically available; 2. recorded w/o identifiers, 3. covered by HIPAA, OR 4. Research by or on behalf of federal agencies or departments 	HIPAA Waivers may still be necessary
<ul style="list-style-type: none"> • <u>Storage of identifiable data</u> for Secondary research 	Must use Broad Consent and get Limited IRB Review	Only applies to <u>identifiable</u> data to be saved for future <u>unspecified</u> research
<ul style="list-style-type: none"> • <u>Use of identifiable data</u> for Secondary research 	Must use Broad Consent and get Limited IRB Review	IRB review that research to be conducted is consistent with broad consent

Medical Human Subjects Research – Some of the Changes To Common Rule; Effective Date 7/19/2018

Category	Changes	Comments
<ul style="list-style-type: none"> • “Regular” Consent 	<p>Focused presentation of key elements first – reason to participate or not.</p> <p>Requirement to post federally sponsored <u>clinical trial (includes behavioral health-related)</u> consent form on public website 60 days after study close.</p>	<p><u>1 New regular element</u>: removal of identifiers to use data/specimens for future use, OR no future use even if de-identified.</p> <p><u>3 New ‘additional’ elements</u> for collecting/using identifiable data/specimens, as appropriate:</p> <ul style="list-style-type: none"> ▪Commercial profit ▪Return of results ▪Whole genome sequencing
<ul style="list-style-type: none"> • Broad Consent 	<p>12 Specified elements cannot be changed or altered, but waiver of documentation (signature) okay</p>	
<ul style="list-style-type: none"> • Waiver of Documentation (signature) 	<p><u>New allowable criteria</u>: signing is not a cultural norm and research is minimal risk</p>	
<ul style="list-style-type: none"> • Waiver of Regular Consent for use of Identifiable Data/specimens 	<p>IRB must find that it is not practicable to use nonidentifiable data/specimens</p>	
<ul style="list-style-type: none"> • Screening exception 	<p>No informed consent required for recruiting, screening, determining eligibility if part of a study, not a stand-alone procedure</p>	<p>FDA not (yet) in sync; Waiver of HIPAA Authorization for recruitment may still be required</p>
Streamlining		
<ul style="list-style-type: none"> • Continuing review 	<p>No longer required for Minimal Risk or regular study when in data analysis</p>	<p>Includes analysis of <u>identifiable data</u></p>
<ul style="list-style-type: none"> • (Federal) Grant Review 	<p>IRB No longer required to review</p>	
Single IRB		
<ul style="list-style-type: none"> • Cooperative Research (SIRB) 	<p>Mandated for > than 1 site for (federally funded) research</p>	<p>Effective 1/20/2020</p>